We recently compiled a list of the 12 Best Healthcare Stocks to Buy According to Analysts. In this article, we are going to ...

Patients with relapsing-remitting multiple sclerosis (RRMS) in England, Wales and Northern Ireland can now access treatment with Biogen's oral therapy Vumerity, after NICE recommended the drug for ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

They also emphasized continued interest in neurology while acknowledging the strength of Biogen’s immunology capabilities from its multiple sclerosis franchise and the need to diversify further.

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

2024 Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs. Biogen lifts annual profit forecast ...

BTIG analyst Thomas Shrader has maintained their neutral stance on BIIB stock, giving a Hold rating on January 23.Invest with Confidence: ...

The company's future hinges on the success of key products like Leqembi for Alzheimer's disease and Skyclarys for Friedreich's ataxia, while grappling with an underdeveloped pipeline and a declining ...